Neelim Healthcare Consulting
Neelim

Pharmacist Prometric exam questions

Therapeutics, calculations, compounding, law and pharmacovigilance.

Tell us which regulator you are sitting and we send the bank prepared for that authority's exam.

For DHA · DOH · MOHAP · SHA · SCFHS · QCHP · NHRA · OMSB · Kuwait MOHDHA PHO5481OMSB OEPPass mark DHA 60% · QCHP 60% · OMSB 60%4 papers · 549 Qs
AED 249one-time
About a quarter of one exam fee
Request this question bank

Tell us your authority and we send the bank for that exam, usually the same day.

Or sit 25 questions free first →

What is riding on this exam

~AED 880
DHA exam fee, per attempt
Paid again on every re-sit. Other regulators' fees are in the table below.
3
UAE attempts - in total
Shared across DHA, DOH, MOHAP and SHA, not three each. Saudi, Qatar, Oman and Kuwait rules are in the FAQ.
60%
Pass mark, by regulator
DHA 60%, QCHP 60%, OMSB 60%. Other regulators in the table below.

One failed attempt costs you the fee again, plus months of delay on your licence, your visa and your start date. This bank costs about a quarter of one exam fee.

Every regulator: format, pass marks and fees for all GCC licensing exams, each from the regulator's own documents.

The Pharmacist exam at a glance

DHA (UAE) publishes a Pharmacist exam of 150 MCQs in 3 hours with a 60% pass mark; SCFHS (Saudi Arabia) publishes a Pharmacist exam of 200 MCQs in 240 minutes with a 536 on a 200-800 scale pass mark; QCHP (Qatar) publishes a Pharmacist exam of 150 MCQs in 3 hours with a 60% pass mark; OMSB (Oman) publishes a Pharmacist exam of 100 MCQs in 150 minutes with a 60% pass mark. DOH, MOHAP, SHA, NHRA, Kuwait MOH do not publish Pharmacist-specific figures; their regulator-wide format and pass-mark rules are in the full table.

DHA · UAE
Pharmacist (PHO5481)
150 MCQs in 3 hours · pass mark 60% · USD 240 (about AED 880) · checked September 2026
SCFHS · Saudi Arabia
Saudi Pharmacist Licensure Examination (SPLE)
200 MCQs in 240 minutes · pass mark 536 on a 200-800 scale · checked October 2026
QCHP · Qatar
Pharmacist
150 MCQs in 3 hours · pass mark 60% · checked September 2026
OMSB · Oman
Omani Examination for Pharmacists (OEP)
100 MCQs in 150 minutes · pass mark 60% · USD 200 (about OMR 80) · checked September 2026

From each regulator's own exam documents; the DHA row is from the DHA CBT Guideline, Sep 2026. Every other regulator is in the full GCC table.

Try two questions from this bank

Original questions from the bank - pick an answer to see the rationale and reference.

Q1Pharmaceutical Calculations & Compounding

A chemotherapy agent is ordered at 50 mg/m² for a patient with a body surface area of 1.6 m². What is the calculated dose?

Choose an answer to see the rationale.

Q2Pharmaceutical Calculations & Compounding

A TPN order requires 50 g of dextrose. Using a 70% dextrose stock solution, what volume is needed?

Choose an answer to see the rationale.

Not sure where you stand? Sit 25 of these questions free, timed at real exam pace, and see which domains you are weakest in.

Take the free mock exam →

Liked those? The full bank has 549 questions at this standard - every one with a rationale and a reference.

Get the full bank - AED 249

What's inside

  • ✓4 full-length papers (~135 Q each)
  • ✓549 questions, no overlap between papers
  • ✓Four options, one unambiguous best answer
  • ✓A full rationale on every question
  • ✓A real guideline or textbook reference
  • ✓Every sub-topic in the published blueprint
  • ✓Researched by Neelim's exam research team
  • ✓Prepared for your authority's exam, not a generic set

The Pharmacist exam in every GCC country

Pharmacist licensing exam in every GCC country
RegulatorExamFormatPass markFee per attempt
Pharmacist (PHO5481)
150 MCQs in 3 hours60%USD 240 (about AED 880)
SCFHS
Kingdom of Saudi Arabia
Practise →
200 MCQs in 240 minutes536 on a 200-800 scaleNot published
QCHP
State of Qatar
Practise →
Pharmacist
150 MCQs in 3 hours60%Not published
OMSB
Sultanate of Oman
Practise →
Omani Examination for Pharmacists (OEP)
100 MCQs in 150 minutes60%USD 200 (about OMR 80)
DOH
Abu Dhabi, Al Ain and Al Dhafra
Practise →
DOH licensing exam
Regulator-wide format
Written + oral/OSCEPass / fail onlyNot published
MOHAP
Northern Emirates - Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah
Practise →
MOHAP licensing exam
Regulator-wide format
Computer-basedNot publishedNot published
SHA
Emirate of Sharjah
Practise →
SHA licensing exam
Regulator-wide format
Set at assessmentNot publishedNot published
NHRA
Kingdom of Bahrain
Practise →
NHRA licensing exam
Regulator-wide format
Prometric CBTNot publishedNot published
Kuwait MOH
State of Kuwait
Practise →
Kuwait MOH licensing exam
Regulator-wide format
150 MCQs, 170 min60-70%Not published

Highlighted rows publish figures for this exact Pharmacist exam; the others show the regulator's general rules.

From each regulator's own exam pages; anything a regulator does not publish says so. Assessment mode also depends on your licence title, so confirm your route on your eligibility notice.

Try 30 free Pharmacist questions with answersDifferent from the samples on this page - each with a full explanationStart →

What the Pharmacist exam covers

The published blueprint for this exam breaks into 13 domains and 183 testable sub-topics. Our bank covers every one of them - here is the full map, so you can see exactly what you are expected to know.

Clinical Therapeutics & Disease-State Management~30% (DHA lists 'Pharmaceutical Care & Disease State Management' at 35%; SCFHS Clinical Sciences 35%)22 topics
  • Hypertension: JNC/ACC-AHA staging, first-line agents (thiazides, ACEi, ARB, CCB), compelling indications, resistant HTN, hypertensive emergency
  • Dyslipidemia: statin intensity, LDL/ASCVD risk, ezetimibe, PCSK9 inhibitors, fibrates, statin myopathy monitoring
  • Ischemic heart disease, acute coronary syndrome, antiplatelets (aspirin, clopidogrel, ticagrelor), nitrates
  • Heart failure (HFrEF/HFpEF): ACEi/ARNI, beta-blockers, MRAs, SGLT2i, diuretics, digoxin
  • Arrhythmias and anticoagulation: atrial fibrillation, warfarin (INR, interactions, reversal), DOACs, heparin/LMWH, VTE treatment and prophylaxis
  • Diabetes mellitus type 1 & 2: ADA targets/HbA1c, metformin, sulfonylureas, DPP-4i, GLP-1 RA, SGLT2i, insulin regimens, hypoglycemia, DKA/HHS
  • +16 more in the bank
Pharmacology, Drug Classes, ADRs & Drug Interactions~12% (est.; core of SCFHS Pharmaceutical Sciences 35%)15 topics
  • Mechanisms of action across major drug categories including biologics
  • Pharmacodynamics: receptor theory, agonists/antagonists, dose-response, potency vs efficacy, therapeutic index
  • Autonomic pharmacology: cholinergic, anticholinergic, adrenergic and antiadrenergic agents
  • Cardiovascular, renal and diuretic pharmacology
  • CNS pharmacology: sedatives, anesthetics, antiepileptics, antidepressants, antipsychotics
  • Endocrine pharmacology: insulin, oral hypoglycemics, thyroid, corticosteroids, sex hormones
  • +9 more in the bank
Pharmaceutical Calculations & Compounding~12% (DHA 'Pharmacy Calculation & Compounding' 15%; SCFHS Sterile/Nonsterile Compounding)15 topics
  • Systems of measurement, metric conversions, and household equivalents
  • Concentration expressions: percentage strength (w/w, w/v, v/v), ratio strength, ppm
  • Dilution and concentration, alligation medial and alligation alternate
  • Dosage and dose calculations by body weight and body surface area (BSA)
  • Pediatric dose calculations (Clark's, Young's rules) and mg/kg dosing
  • IV flow rate, drip rate (gtt/min), and infusion time calculations
  • +9 more in the bank
Pharmaceutics, Biopharmaceutics & Pharmacokinetics~8% (est.; SCFHS Pharmaceutics 2.4 & Pharmacokinetics 2.5)15 topics
  • Dosage form design: solid, liquid, semisolid, controlled/modified release, patches, implants
  • Biopharmaceutical principles of drug delivery and release from dosage forms
  • Physicochemical properties affecting drug entities and dosage forms (solubility, partition coefficient, pKa)
  • Materials, excipients and methods used in dosage-form preparation
  • Drug and dosage-form stability: chemical degradation kinetics and physical instability
  • Principles of biotechnology-derived products and their application
  • +9 more in the bank
Medicinal Chemistry, Pharmacognosy & Dietary Supplements~6% (est.; SCFHS Medicinal Chemistry 2.1 & Pharmacognosy 2.3)11 topics
  • Physicochemical properties of drugs in relation to ADME
  • Chemical basis for drug action and fundamental pharmacophores by disease
  • Structure-activity relationships and drug-receptor interactions
  • Chemical pathways of drug metabolism (phase I and phase II)
  • Application of SAR to drug-therapy decisions
  • Crude drugs, semi-purified and purified natural products
  • +5 more in the bank
Basic Biomedical Sciences~6% (SCFHS Basic Biomedical Sciences 10%)13 topics
  • Physiology: function of major body systems and homeostasis at organ/system level
  • Biochemistry of biomacromolecules: proteins, lipids, carbohydrates, nucleic acids
  • Intermediary and energy metabolism and nutritional molecules
  • Enzymology, coenzymes and enzyme kinetics
  • Cell chemistry and signal transduction pathways
  • DNA/RNA science, protein synthesis and molecular genetics
  • +7 more in the bank
Nonprescription (OTC) & Self-Care / Counter Medication~6% (DHA 'Counter Medication' 10%)12 topics
  • Triage and identifying when to refer to a physician vs self-treat
  • Analgesics and antipyretics OTC (paracetamol/acetaminophen, ibuprofen dosing and limits)
  • Cough, cold and allergy products; decongestants and antihistamines
  • Gastrointestinal OTC: antacids, laxatives, antidiarrheals, antiemetics
  • Dermatologic OTC: antifungals, hydrocortisone, acne, wound care
  • Ophthalmic and otic OTC products
  • +6 more in the bank
Special Populations~5% (DHA lists Pregnancy/Lactation 5%, Pediatrics 5%, Geriatrics 5%)12 topics
  • Pregnancy: drug safety categories, teratogens, and managing chronic conditions in pregnancy
  • Lactation: drug transfer into breast milk and compatible/incompatible medications
  • Neonatal and pediatric pharmacotherapy: weight-based dosing and developmental pharmacokinetics
  • Pediatric formulation and palatability considerations
  • Geriatric pharmacotherapy: physiologic changes affecting PK/PD
  • Beers Criteria and potentially inappropriate medications in the elderly
  • +6 more in the bank
Toxicology & Poisoning Management~5% (DHA Toxicology 5%; SCFHS acute/chronic toxicity)12 topics
  • Acute and chronic drug and chemical overdose principles
  • Common poisonings and specific antidotes (paracetamol/N-acetylcysteine, opioids/naloxone, benzodiazepines/flumazenil)
  • Anticoagulant reversal (vitamin K, protamine, idarucizumab, andexanet)
  • Organophosphate poisoning (atropine, pralidoxime) and cholinergic toxidromes
  • Heavy-metal poisoning and chelation therapy (lead, iron/deferoxamine, mercury, arsenic)
  • Methanol/ethylene glycol (fomepizole, ethanol) and toxic alcohols
  • +6 more in the bank
Patient Assessment, Counseling, Drug Information & Evidence-Based Practice~5% (est.; SCFHS Clinical 4.1, 4.5 & Professional Communication 3.8)14 topics
  • Obtaining a comprehensive patient and medication history
  • Performing and interpreting patient physical assessment findings
  • Interpreting clinical laboratory values and diagnostic tests
  • Identifying and prioritizing drug-related problems
  • Medication therapy management (MTM) and medication reconciliation
  • Patient counseling technique on all pharmaceutical agents, storage and administration
  • +8 more in the bank
Pharmacy Law, Ethics & Regulatory Affairs~6% (DHA Law & Ethics 10%; SCFHS 3.5 & 3.7)14 topics
  • Legal and regulatory principles applied to dispensing and professional services
  • Controlled substances and narcotics regulations, scheduling and record-keeping
  • Prescription-only vs nonprescription vs controlled medication classification
  • Authority and role of health authorities (DHA, DOH, MOHAP, SCFHS/SFDA, QCHP, NHRA, OMSB)
  • Pharmacy licensing, registration and DataFlow verification requirements
  • Prescription requirements, validity and dispensing rules in the GCC
  • +8 more in the bank
Public Health, Pharmacoeconomics, Pharmacoepidemiology & Biostatistics~5% (est.; SCFHS Social/Behavioral/Administrative 3.1-3.3, 3.6)14 topics
  • Organization of health-care delivery systems in the GCC
  • Social, political and economic factors influencing health-care delivery
  • Public health and wellness: chronic-disease prevention, health promotion, infectious-disease control
  • Demographics and environmental factors leading to disease
  • Role of immunizations in disease prevention and health promotion
  • Pharmacoepidemiology: data sources and study designs to estimate benefit/risk in populations
  • +8 more in the bank
Pharmacy Practice Management, Medication Safety & Dispensing Systems~5% (DHA Medication Safety 5%; SCFHS 3.4 & 3.10)14 topics
  • Management principles: planning, organizing, directing and controlling pharmacy resources
  • Inventory management, procurement, storage and cold-chain requirements
  • Marketing, pricing, distribution and promotion of pharmacy products/services
  • Accounting, budgeting and financial management
  • Systems for safe and effective preparation and dispensing across practice settings
  • Pharmacy informatics, automation and information-management technology
  • +8 more in the bank

12 worked Pharmacist practice questions

Original exam-style questions from the bank, spread across the blueprint domains. They are not real or recalled exam questions. Try each one, then open the answer for the rationale and reference. None of them appear in the free mock exam, so reading them will not spoil it.

  1. Question 1 · Clinical Therapeutics & Disease-State Management

    A patient with HIV is being counseled that antiretroviral therapy involves a combination regimen rather than a single drug. What is the primary rationale for using combination antiretroviral therapy (typically three active agents)?

    1. ATo reduce the number of daily tablets to one
    2. BTo maximally suppress viral replication and prevent emergence of resistance
    3. CTo eliminate the need for adherence to therapy
    4. DTo cure the infection completely within weeks
    Show answer and explanation

    Correct answer: B. To maximally suppress viral replication and prevent emergence of resistance

    Combination antiretroviral therapy using agents from different classes achieves durable maximal viral suppression and prevents the emergence of drug resistance that would occur rapidly with monotherapy. ART controls but does not cure HIV, adherence remains essential, and pill burden reduction is a formulation convenience rather than the core rationale.

    Reference: DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2023; WHO HIV guidelines

  2. Question 2 · Pharmaceutical Calculations & Compounding

    A disinfectant is prepared at a ratio strength of 1:2500. What is this concentration expressed in parts per million (ppm)?

    1. A40 ppm
    2. B250 ppm
    3. C400 ppm
    4. D2500 ppm
    Show answer and explanation

    Correct answer: C. 400 ppm

    A ratio strength of 1:2500 means 1 part in 2500 parts; dividing 1,000,000 by 2500 gives 400 ppm. The other options misplace the decimal or invert the ratio.

    Reference: Ansel's Pharmaceutical Calculations, 15th ed. (2017)

  3. Question 3 · Medicinal Chemistry, Pharmacognosy & Dietary Supplements

    Levodopa is used in Parkinson's disease rather than dopamine itself. Which combined rationale best explains this choice?

    1. ADopamine is a prodrug that must be converted to levodopa peripherally
    2. BDopamine crosses the blood-brain barrier more readily than levodopa
    3. CLevodopa is the inactive D-isomer that is safer than dopamine
    4. DLevodopa is an amino-acid prodrug that crosses the blood-brain barrier via an active transporter and is then decarboxylated to dopamine centrally
    Show answer and explanation

    Correct answer: D. Levodopa is an amino-acid prodrug that crosses the blood-brain barrier via an active transporter and is then decarboxylated to dopamine centrally

    Dopamine does not cross the blood-brain barrier, so its metabolic precursor levodopa (L-DOPA) is given as a prodrug; being an amino acid, it is carried across the barrier by the large neutral amino-acid transporter and is then decarboxylated to dopamine within the CNS. It is the pharmacologically relevant L-isomer (not the inactive D-form), and it is levodopa, not dopamine, that penetrates the brain.

    Reference: Katzung Basic & Clinical Pharmacology, 15th ed. (2021), antiparkinsonian drugs

  4. Question 4 · Nonprescription (OTC) & Self-Care / Counter Medication

    A patient presents with a minor superficial skin abrasion. Which self-care wound advice is most appropriate?

    1. AApply undiluted hydrogen peroxide daily to the healing wound
    2. BClean gently with water, keep it moist and covered, and refer if signs of infection develop
    3. CLeave it uncovered and apply an oral antibiotic
    4. DApply a potent topical corticosteroid to speed healing
    Show answer and explanation

    Correct answer: B. Clean gently with water, keep it moist and covered, and refer if signs of infection develop

    Minor abrasions should be gently cleaned (e.g., with clean water), kept moist and covered to promote healing, with referral if signs of infection (spreading redness, pus, fever) appear. Repeated undiluted hydrogen peroxide damages healing tissue, oral antibiotics are unnecessary for a simple abrasion, and topical corticosteroids can impair wound healing.

    Reference: Handbook of Nonprescription Drugs (APhA), 2021 - Minor wound care; NICE CKS Lacerations

  5. Question 5 · Special Populations

    A 24-year-old woman with epilepsy controlled on valproate wishes to become pregnant. Regarding valproate use in pregnancy, which statement is most accurate?

    1. AValproate carries the highest risk of neural tube defects and impaired neurodevelopment among common antiepileptics
    2. BValproate is considered the safest antiepileptic in pregnancy
    3. CFolic acid supplementation eliminates the teratogenic risk of valproate
    4. DValproate should be switched to phenytoin, which is non-teratogenic
    Show answer and explanation

    Correct answer: A. Valproate carries the highest risk of neural tube defects and impaired neurodevelopment among common antiepileptics

    Valproate has the highest teratogenic risk among common antiepileptics, causing neural tube defects and a dose-dependent reduction in childhood IQ/neurodevelopment, so it should be avoided in women of childbearing potential when alternatives exist. Folic acid reduces but does not eliminate neural tube defect risk. Phenytoin is also teratogenic (fetal hydantoin syndrome), so it is not a non-teratogenic substitute.

    Reference: NICE Epilepsy Guideline NG217 (2022); MHRA Valproate Pregnancy Prevention Programme

  6. Question 6 · Patient Assessment, Counseling, Drug Information & Evidence-Based Practice

    When appraising a randomized controlled trial for internal validity, which methodological feature MOST directly reduces the risk of selection bias?

    1. AAllocation concealment during randomization
    2. BUsing a large sample size
    3. CReporting results as relative risk
    4. DPublishing in a high-impact journal
    Show answer and explanation

    Correct answer: A. Allocation concealment during randomization

    Allocation concealment prevents those enrolling participants from knowing or influencing the next assignment, directly protecting against selection bias and ensuring comparable groups at baseline. A large sample improves precision but not freedom from bias, and the choice of effect measure or journal prestige does not address internal validity. Concealed allocation is a core determinant of a trial's methodological quality.

    Reference: Higgins et al., Cochrane Handbook for Systematic Reviews of Interventions, 2019

  7. Question 7 · Pharmacy Practice Management, Medication Safety & Dispensing Systems

    According to USP <800>, which engineering control is required for compounding sterile hazardous drugs to protect both the preparation and the operator?

    1. AA horizontal laminar airflow bench blowing air toward the operator
    2. BA containment primary engineering control such as a biological safety cabinet or compounding aseptic containment isolator, in a negative-pressure room
    3. CAn open workbench with a desk fan
    4. DA standard fume hood vented into the pharmacy
    Show answer and explanation

    Correct answer: B. A containment primary engineering control such as a biological safety cabinet or compounding aseptic containment isolator, in a negative-pressure room

    USP <800> requires sterile hazardous-drug compounding within a containment primary engineering control (for example, a Class II biological safety cabinet or compounding aseptic containment isolator) located in an externally vented, negative-pressure containment area to protect both product sterility and the worker. A horizontal laminar bench blows contaminants toward the operator, and open benches, desk fans, or internally recirculating hoods provide no adequate containment.

    Reference: USP General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings (2020)

  8. Question 8 · Pharmacology, Drug Classes, ADRs & Drug Interactions

    A 65-year-old man with a history of tendon disorders needs treatment for a urinary infection. Which class carries a black-box warning for tendinitis and tendon rupture that should influence antibiotic choice?

    1. AFluoroquinolones
    2. BMacrolides
    3. CFirst-generation cephalosporins
    4. DNitrofurantoin
    Show answer and explanation

    Correct answer: A. Fluoroquinolones

    Fluoroquinolones carry black-box warnings including tendinitis and tendon rupture (risk increased in older patients and with concurrent corticosteroids), so alternatives are preferred when possible. Macrolides, cephalosporins, and nitrofurantoin do not carry this specific tendon-rupture warning.

    Reference: US FDA Drug Safety Communication on fluoroquinolones (2016, updated)

  9. Question 9 · Pharmaceutics, Biopharmaceutics & Pharmacokinetics

    A drug is a weak acid that is filtered and undergoes passive tubular reabsorption. In an overdose, alkalinizing the urine with sodium bicarbonate enhances its elimination. What is the mechanism?

    1. AAlkaline urine converts the acid to its unionized form, increasing reabsorption
    2. BAlkalinization inhibits active tubular secretion of the drug
    3. CAlkalinization increases glomerular filtration rate directly
    4. DAlkaline urine ionizes the weak acid, trapping it in the tubular lumen and reducing reabsorption
    Show answer and explanation

    Correct answer: D. Alkaline urine ionizes the weak acid, trapping it in the tubular lumen and reducing reabsorption

    Raising urinary pH ionizes a weak acid (such as salicylate or phenobarbital); the ionized species is lipid-insoluble and cannot be passively reabsorbed, so it is trapped in the tubular lumen and excreted more rapidly (ion trapping). Alkalinization does not primarily change GFR or active secretion, and it decreases, not increases, reabsorption.

    Reference: Katzung, Basic & Clinical Pharmacology, 15th ed., 2021

  10. Question 10 · Basic Biomedical Sciences

    A microbiology report describes an acid-fast bacillus that resists standard Gram staining because of its lipid-rich cell wall and requires the Ziehl-Neelsen stain. This staining property is due to a high content of which cell-wall component?

    1. ATeichoic acid
    2. BLipopolysaccharide
    3. CMycolic acid
    4. DLipoteichoic acid
    Show answer and explanation

    Correct answer: C. Mycolic acid

    Acid-fast organisms such as Mycobacterium species have cell walls rich in mycolic acids (long-chain fatty acids), which make them resist decolorization by acid-alcohol and require the Ziehl-Neelsen technique. Teichoic and lipoteichoic acids are gram-positive wall components, and lipopolysaccharide is a gram-negative outer-membrane component; none confer acid-fastness.

    Reference: Murray Medical Microbiology, 9th ed., 2021

  11. Question 11 · Pharmacy Law, Ethics & Regulatory Affairs

    Which of the following adverse events should most clearly be prioritized for expedited pharmacovigilance reporting?

    1. AA serious, unexpected reaction such as an unlabeled anaphylactic or hepatotoxic event, especially with a newly marketed medicine
    2. BA mild, well-documented transient headache from a long-established drug
    3. CA patient's dislike of a tablet's taste
    4. DA minor, self-limiting reaction already described in the product label
    Show answer and explanation

    Correct answer: A. A serious, unexpected reaction such as an unlabeled anaphylactic or hepatotoxic event, especially with a newly marketed medicine

    Serious and unexpected (not previously labeled) reactions, particularly with newer medicines, warrant expedited reporting because they may reflect important new safety signals. Mild, well-characterized, expected, or trivial events such as taste complaints carry far less surveillance value and do not require expedited reporting.

    Reference: CIOMS/WHO pharmacovigilance reporting standards; WHO Pharmacovigilance guidance (2002)

  12. Question 12 · Special Populations

    A patient is a CYP2C19 poor metabolizer. Which antiplatelet drug's effectiveness is most likely reduced, prompting consideration of an alternative agent after PCI?

    1. AClopidogrel
    2. BPrasugrel
    3. CTicagrelor
    4. DAspirin
    Show answer and explanation

    Correct answer: A. Clopidogrel

    Clopidogrel is a prodrug requiring CYP2C19 activation; poor metabolizers form less active drug, reducing antiplatelet effect and increasing cardiovascular events, so prasugrel or ticagrelor (not CYP2C19-dependent) are preferred alternatives. Aspirin acts by an unrelated mechanism (COX inhibition) and is unaffected by CYP2C19 status.

    Reference: CPIC Guideline for Clopidogrel and CYP2C19 (2013, updated 2022)

Pharmacist reference books and guidelines

Every question in this bank names the textbook or guideline its answer rests on. These are the sources our Pharmacist questions cite most often - the reading list to revise from alongside the bank.

Textbooks

10
  1. 1

    Ansel's Pharmaceutical Calculations

    16th edition
  2. 2

    Handbook of Nonprescription Drugs (APhA)

    2021
  3. 3

    Guyton and Hall Textbook of Medical Physiology

    14th edition2020
  4. 4

    Goldfrank's Toxicologic Emergencies

    11th edition2019
  5. 5

    Katzung Basic & Clinical Pharmacology

    15th edition2021
  6. 6

    Lehninger Principles of Biochemistry

    8th edition2021
  7. 7

    Goodman & Gilman's The Pharmacological Basis of Therapeutics

    14th edition2023
  8. 8

    Foye's Principles of Medicinal Chemistry

    8th edition2019
  9. 9

    Trease and Evans' Pharmacognosy

    16th edition2009
  10. 10

    Sinko, Martin's Physical Pharmacy and Pharmaceutical Sciences

    7th edition2016

Guidelines and standards

10
  1. 1

    AHA/ACC/HFSA Heart Failure Guideline

    2022
  2. 2

    WHO Adherence to Long-Term Therapies

    2003
  3. 3

    AHA/ACC Cholesterol Guideline

    2018
  4. 4

    Endocrine Society Hypertriglyceridemia Guideline

    2012
  5. 5

    WHO Guide to Good Prescribing

    1994
  6. 6

    ESC Heart Failure Guidelines

    2021
  7. 7

    ACC/AHA Stable Ischemic Heart Disease Guideline

    2014
  8. 8

    KDIGO Diabetes in CKD Guideline

    2022
  9. 9

    DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

    2023
  10. 10

    NICE Epilepsy Guideline

    NG2172022

Sitting the SPLE? SCFHS publishes its own list: SCFHS's SPLE reading list. Where your regulator publishes a reading list, use the editions it names. Exam questions are not taken from any one book.

Last reviewed September 2026

About these questions: every question is original, researched by Neelim's exam research team, written to the published blueprint, with a rationale and a reference. No recalled or leaked exam content is used. How we write our questions.

Frequently asked questions

Are these real Pharmacist exam questions?
No. Every item is original, researched by Neelim's exam research team against the exam blueprint published by the health authorities. Real, recalled or leaked exam content breaches the testing bodies' rules and can lead to a permanent exam ban - we do not sell it, and neither should anyone else.
How many questions are in the Pharmacist bank?
549 original questions across 4 full-length papers of roughly 135 questions each (the DHA exam itself is 150 questions). The papers do not overlap, so you get 549 distinct items covering every sub-topic in the published blueprint.
What is the pass mark for the DHA Pharmacist exam?
60%. DHA publishes the pass score for each exam, and 60% is the figure for Pharmacist (PHO5481) in the DHA CBT Guideline, Sep 2026. The result is posted to your Sheryan account as Pass or Fail only - your score is not shared. Elsewhere in the GCC: DOH Pass / fail only (regulator-wide), SCFHS 536 on a 200-800 scale, QCHP 60%, OMSB 60%, Kuwait MOH 60-70% (regulator-wide).
How many questions are in the DHA Pharmacist exam, and how long is it?
150 multiple-choice questions in 3 hours, and the time includes registration and the introduction. It is a computer-based test delivered by Prometric at test centres in the UAE and abroad.
How much does the DHA Pharmacist exam cost?
USD 240 (about AED 880) per attempt, paid again for every re-sit. DHA also charges a flat AED 200 credentialing fee through Sheryan.
How many attempts do I get?
In the UAE, three in total across DHA, DOH, MOHAP and SHA, not three each, under clause 1.5.4 of the Unified PQR (April 2025). Clause 1.5.5 allows one further attempt with a different authority, except on the Consultant route. Elsewhere in the GCC: SCFHS up to 4 a year, QCHP 5 per scope, OMSB no set maximum, Kuwait MOH 3, 6 weeks apart.
Does this cover DHA, DOH, MOHAP, SCFHS and the other GCC regulators?
Yes, and it is not a generic set. Tell us which regulator you are sitting and we send the bank prepared for that authority's exam: its blueprint, its exam length and pass mark, and its local regulations. The core clinical knowledge is shared across the GCC; what changes by regulator is the test vendor (Prometric for DHA, SCFHS, QCHP, NHRA, Kuwait MOH; Pearson VUE for DOH, OMSB), the exam length, the pass mark, the local-regulation questions and, at some regulators such as DOH, an added oral or OSCE component. The table on this page shows each regulator's published format, pass mark and fee, and says where a figure is not published.
How do I receive it?
As PDF files. Card checkout is being set up, so for now you request it from this page and we send it to you directly, usually the same day.

Still unsure whether you even need this exam?

Your route depends on your profession, your licence title and the authority. We have guided over 1,000 professionals through GCC licensing - tell us your situation and we will confirm exactly what you need to sit.